Pozen.

PositionTRIANGLE

CHAPEL HILL -- Drug developer Pozen will get a $20 million payment from British drug maker GlaxoSmithKline for a compound they are developing. The U.S. Food and Drug Administration will review an application to...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT